panel-discussion
As more and more platforms and instruments come to play in the biomarker research, the method development and validation for biomarkers become more and more complex. Best regulatory practice in analyzing biomarkers to support drug development is expected, but deciding which regulation to follow has not been consistent.
Register to gain access to gated resources.
"*" indicates required fields